Jinok Chung, DO
Interventional Cardiology · McAlester, OKNPI 1841385325
Payments from drug & device makers
What this record shows
Medtronic accounts for 62.2% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $1,720, 9.8 times the $176 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in OK, where the typical reported total is $7,360.
Across 53 payments — averaging $44.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Boston Scientific$198
- E.r. Squibb & Sons, L.L.C.$159
- Abbott$153
- Pfizer$118
- Irhythm Technologies, Inc.$73
- plus $198 from 7 others
What the payments were for
- Travel & lodging$1,08546%
- Food & beverage$1,29154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 10 | $1,477 |
| Boston Scientific | 6 | $198 |
| E.r. Squibb & Sons, L.L.C. | 9 | $159 |
| Abbott | 4 | $153 |
| Pfizer | 7 | $118 |
| Irhythm Technologies, Inc. | 3 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $68 |
| Merck | 3 | $47 |
| Novartis | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $19 |
| Fisher & Paykel Healthcare Inc | 1 | $19 |
| AstraZeneca | 1 | $13 |
| Edwards Lifesciences | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,289
How this compares
$2,376 in reported general payments places this provider in the 20th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 189 | $201,191 |
| XareltoRivaroxaban | 61 | $56,906 |
| EntrestoSacubitril/Valsartan | 43 | $51,989 |
| BrilintaTicagrelor | 14 | $17,231 |
| Isosorbide Dinitrate | 331 | $13,814 |
| Ranolazine ErRanolazine | 71 | $5,310 |
| Atorvastatin Calcium | 236 | $3,235 |
| Amiodarone Hcl | 76 | $3,184 |
| ClopidogrelClopidogrel Bisulfate | 213 | $3,100 |
| Metoprolol Tartrate | 363 | $2,604 |
| Metoprolol Succinate | 165 | $1,892 |
| Potassium Chloride | 89 | $1,696 |
| Prasugrel Hcl | 13 | $1,371 |
| Carvedilol | 127 | $1,166 |
| Atenolol | 158 | $1,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $118 | $201,191189 claims |
| NovartisEntresto | $22 | $51,98943 claims |
| AstraZenecaBrilinta | $13 | $17,23114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in McAlester
- Kamran MuhammadTulsa$1.4M
- George ChrysantOklahoma City$524K
- Suresh ChandrasekaranMidwest City$302K
- Jeffrey SparlingOklahoma City$231K
- Stanley ZimmermanTulsa$93K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Marcus SmithOklahoma City$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.